Jeil Pharma Holdings Inc (KRX:002620)
South Korea · Delayed Price · Currency is KRW 8,210.00
+70.00 (0.86%)
At close: Feb 20, 2026
Jeil Pharma Holdings Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -29,412 | -51,159 | -16,250 | -74,556 | -3,482 | 11,431 |
Depreciation & Amortization | 14,673 | 14,099 | 12,556 | 10,905 | 8,983 | 8,651 |
Loss (Gain) From Sale of Assets | -13.83 | -7.97 | -0.53 | -23.98 | -1,930 | -7.64 |
Asset Writedown & Restructuring Costs | 45,204 | 45,204 | 28,604 | 78,335 | 16,388 | - |
Loss (Gain) From Sale of Investments | -5,948 | -5,586 | -2,916 | -6,271 | -20,857 | -11,580 |
Loss (Gain) on Equity Investments | -18,417 | -9,855 | -9,329 | -5,708 | -8,452 | -7,290 |
Stock-Based Compensation | 774.82 | 1,026 | 578.03 | 472.48 | 163.17 | 80.04 |
Provision & Write-off of Bad Debts | -225.29 | -682.67 | -2,423 | -308.41 | 1,669 | 176.69 |
Other Operating Activities | 31,127 | 26,151 | 13,309 | 2,014 | 6,516 | 19,551 |
Change in Accounts Receivable | 18,497 | -11,223 | -14,328 | -12,722 | 10,835 | 2,177 |
Change in Inventory | 4,393 | -3,266 | -12,170 | 1,347 | 9,341 | -28,712 |
Change in Accounts Payable | -64,017 | -7,721 | -9,849 | 3,358 | 10,024 | -8,555 |
Change in Other Net Operating Assets | 3,942 | 7,563 | 7,803 | -14,098 | -15,795 | -9,592 |
Operating Cash Flow | 577.2 | 4,542 | -4,416 | -17,256 | 13,403 | -23,671 |
Operating Cash Flow Growth | -96.33% | - | - | - | - | - |
Capital Expenditures | -7,757 | -4,340 | -6,223 | -15,462 | -23,688 | -9,811 |
Sale of Property, Plant & Equipment | 14.2 | 8.35 | 87.64 | 23.98 | 37,800 | 7.64 |
Divestitures | - | - | - | - | - | 6,331 |
Sale (Purchase) of Intangibles | -1,013 | -2,523 | -3,571 | -5,948 | 91.43 | -438.27 |
Investment in Securities | -7,278 | 8,508 | -3,770 | 169.41 | -10,506 | -1,536 |
Other Investing Activities | 14.98 | 620.43 | 51.01 | 106.46 | 3,627 | 3,840 |
Investing Cash Flow | -16,020 | 2,274 | -13,425 | -21,110 | 7,325 | -1,606 |
Short-Term Debt Issued | - | 842.51 | 25,834 | 27,163 | - | 28,906 |
Long-Term Debt Issued | - | - | - | - | 12,288 | 4,712 |
Total Debt Issued | 10,877 | 842.51 | 25,834 | 27,163 | 12,288 | 33,618 |
Short-Term Debt Repaid | - | - | - | - | -42,477 | - |
Long-Term Debt Repaid | - | -5,254 | -4,084 | -6,377 | -7,146 | -6,861 |
Total Debt Repaid | 347.53 | -5,254 | -4,084 | -6,377 | -49,623 | -6,861 |
Net Debt Issued (Repaid) | 11,224 | -4,411 | 21,750 | 20,785 | -37,335 | 26,757 |
Issuance of Common Stock | - | - | - | - | 7,498 | 37.91 |
Repurchase of Common Stock | - | - | - | -396.98 | -810.02 | - |
Dividends Paid | -183.17 | -1,134 | -1,134 | -1,475 | -1,590 | -1,586 |
Other Financing Activities | 20,994 | 19,762 | -0 | 26,001 | 20,000 | -314.88 |
Financing Cash Flow | 32,035 | 14,217 | 20,616 | 44,914 | -12,238 | 24,894 |
Foreign Exchange Rate Adjustments | 2,147 | 1,749 | -496.29 | -369.37 | -93.19 | -669.66 |
Net Cash Flow | 18,739 | 22,782 | 2,279 | 6,179 | 8,397 | -1,054 |
Free Cash Flow | -7,180 | 202.38 | -10,638 | -32,717 | -10,284 | -33,482 |
Free Cash Flow Margin | -1.01% | 0.03% | -1.32% | -4.13% | -1.35% | -4.39% |
Free Cash Flow Per Share | -467.80 | 13.18 | -692.99 | -2131.27 | -669.95 | -2181.10 |
Cash Interest Paid | 7,657 | 8,051 | 9,044 | 4,891 | 2,592 | 3,362 |
Cash Income Tax Paid | 5,126 | 3,289 | 2,092 | -596.65 | 5,401 | 8,334 |
Levered Free Cash Flow | -3,733 | 11,675 | -19,889 | -20,230 | 7,866 | -26,675 |
Unlevered Free Cash Flow | 1,042 | 17,221 | -13,219 | -16,510 | 9,921 | -24,678 |
Change in Working Capital | -37,185 | -14,647 | -28,544 | -22,115 | 14,405 | -44,682 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.